Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

JAMA Dermatology, Год журнала: 2020, Номер 156(12), С. 1333 - 1333

Опубликована: Сен. 30, 2020

Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced disease severity in moderate to severe atopic dermatitis (AD) phase 3 monotherapy studies.

Язык: Английский

---

Metabolic orchestration of the wound healing response

Cell Metabolism, Год журнала: 2021, Номер 33(9), С. 1726 - 1743

Опубликована: Авг. 11, 2021

Язык: Английский

---

Metabolic Pathways That Control Skin Homeostasis and Inflammation

Trends in Molecular Medicine, Год журнала: 2020, Номер 26(11), С. 975 - 986

Опубликована: Май 1, 2020

Keratinocytes and skin immune cells are actively metabolizing nutrients present in their microenvironment. This is particularly important common chronic inflammatory diseases such as psoriasis atopic dermatitis, characterized by hyperproliferation of keratinocytes expansion cells, thus suggesting increased cell nutritional requirements. Proliferating express high levels glucose transporter (GLUT)1, l-type amino acid (LAT)1, cationic transporters (CATs). Main metabolic regulators hypoxia-inducible factor (HIF)-1α, MYC, mechanistic target rapamycin (mTOR) control activation, proliferation, cytokine release. Here, we provide an updated perspective regarding the potential role nutrient pathways that could be to keratinocytes, dermatitis.

Язык: Английский

---

Cutaneous barrier dysfunction in allergic diseases

Journal of Allergy and Clinical Immunology, Год журнала: 2020, Номер 145(6), С. 1485 - 1497

Опубликована: Июнь 1, 2020

Язык: Английский

---

OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target

American Journal of Clinical Dermatology, Год журнала: 2024, Номер 25(3), С. 447 - 461

Опубликована: Янв. 18, 2024

Atopic dermatitis (AD) is a chronic, heterogeneous, inflammatory disease characterized by skin lesions, pruritus, and pain. Patients with moderate-to-severe AD experience chronic symptoms, intensified unpredictable flares, often have comorbidities secondary complications, which can result in significant clinical burden that impacts the patient's overall quality of life. The complex interplay immune dysregulation barrier disruption drives pathogenesis, T-cell-dependent inflammation plays critical role patients AD. Despite new targeted therapies, many fail to achieve or sustain their individual treatment goals and/or may not be suitable for tolerate these therapies. There remains need novel, efficacious, well-tolerated therapeutic option deliver durable benefits across heterogeneous patient population. Expression OX40 [tumor necrosis factor receptor superfamily, member 4 (TNFRSF4)], prominent T-cell co-stimulatory molecule, its ligand [OX40L; tumor (TNFSF4)] increased As pathway expansion, differentiation, survival effector memory T cells, targeting might promising approach provide sustained inhibition pathogenic cells associated broad control. Antibodies against [rocatinlimab (AMG 451/KHK4083) telazorlimab (GBR 830)] OX40L [amlitelimab (KY1005)] shown results early-phase studies AD, highlighting importance signaling as target

Язык: Английский

---

The infectious complications of atopic dermatitis

Annals of Allergy Asthma & Immunology, Год журнала: 2020, Номер 126(1), С. 3 - 12

Опубликована: Авг. 7, 2020

ObjectiveAtopic dermatitis (AD) is a chronic inflammatory skin disease that complicated by an increased risk for and systemic infections. Preventive therapy AD based on barrier improvement anti-inflammatory treatments, whereas overt infections require antibiotics or antiviral treatments. This review updates the pathophysiology, diagnosis, management, controversy of antibiotic use, potential treatments infectious complications AD.Data SourcesPublished literature obtained through PubMed database searches clinical pictures.Study SelectionsStudies relevant to mechanisms, AD.ResultsSkin defects, type 2 inflammation, Staphylococcus aureus colonization, cutaneous dysbiosis are major predisposing factors in AD. Although antibiotics, use exacerbation remains controversial.ConclusionInfectious comorbidity not common, bacterial eczema herpeticum can be life-threatening. emphasizes therapy. The requires further studies.

Язык: Английский

---

Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity

The Journal of Allergy and Clinical Immunology In Practice, Год журнала: 2020, Номер 8(6), С. 1840 - 1852

Опубликована: Июнь 1, 2020

Язык: Английский

---

Nomenclature and clinical phenotypes of atopic dermatitis

Therapeutic Advances in Chronic Disease, Год журнала: 2021, Номер 12

Опубликована: Янв. 1, 2021

Atopic dermatitis is a heterogeneous disease and resists classification. In this review, we discuss atopic nomenclature identify morphologic phenotypes, which will facilitate correct diagnoses development of treatment strategies. We support using the term ‘atopic dermatitis’ rather than eczema, because it describes allergic background inflammation (‘itis’) as drivers disease. has many manifestations that vary by topographic area affected, age, or race require consideration in differential diagnosis. Different phenotypes based on morphology location, ethnicity, age are discussed. A better-defined phenotype identification for earlier diagnosis complex condition inform selection most appropriate choice an era targeted therapies may generate more individualized patient care.

Язык: Английский

---

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders

JAMA Dermatology, Год журнала: 2021, Номер 157(6), С. 691 - 691

Опубликована: Май 12, 2021

Baricitinib, an oral selective Janus kinase inhibitor, improved the clinical signs and symptoms of moderate to severe atopic dermatitis in 16-week, phase 3 monotherapy studies, BREEZE-AD1 BREEZE-AD2. Long-term efficacy has not yet been examined.To evaluate long-term (68-week) baricitinib adults with who were treatment responders or partial BREEZE-AD2.Patients completing BREEZE-AD1/BREEZE-AD2 entered ongoing, multicenter, double-blind, extension study BREEZE-AD3. The was initiated on March 28, 2018. Data analyzed December 13, 2019.Responders (patients achieving validated Investigator Global Assessment for Atopic Dermatitis [vIGA-AD] score 0 1 [0,1], 2) at completion remained originally assigned 52 weeks (68 total continuous therapy).The primary end point proportion patients a vIGA-AD 0,1 16, 36, Secondary points included 75% more improvement Eczema Area Severity Index [EASI75] 4-point itch numeric rating scale (NRS), using originating baseline data. Itch data collected during first 16 last visit BREEZE-AD3 visit; therefore, are presented therapy, including 16-week period. Missing imputed by observation carried forward. Modified intention-to-treat analysis used.Of responder/partial responder population, treated baricitinib, 4 mg (n = 70) (mean [SD] age, 36.7 [15.5] years; 42 [60%] men), (0,1) week 45.7% (BREEZE-AD3 baseline) and, 68, 47.1%. Improvement EASI 70.0% 55.7% 68. NRS greater than equal 52.5% 32, 45.9%. Of 2 54) 32.8 [12.7] 28 [51.9%] 46.3% 59.3%. EASI75 74.1% 81.5% 44.2% 39.5%.In this double-blind randomized trials, mg, demonstrated sustained dermatitis.ClinicalTrials.gov Identifier: NCT03334435.

Язык: Английский

---

Early intervention and prevention of allergic diseases

Allergy, Год журнала: 2021, Номер 77(2), С. 416 - 441

Опубликована: Июль 13, 2021

Food allergy (FA) is now one of the most common chronic diseases childhood often lasting throughout life and leading to significant worldwide healthcare burden. The precise mechanisms responsible for development this inflammatory condition are largely unknown; however, a multifactorial aetiology involving both environmental genetic contributions well accepted. A understanding pathogenesis FA an essential first step developing comprehensive prevention strategies that could mitigate epidemic. As it frequently preceded by atopic dermatitis can be prevented early antigen introduction, likely facilitated improper initial presentation immune system. Primary oral exposure antigens allowing via well-developed mucosal system, rather than through disrupted skin epidermal barrier, prevent FA. In review, we present data supporting necessity (1) intact barrier epicutaneous presentation, (2) presence specific commensal bacteria maintain system (3) maternal/infant diet diversity, including vitamins minerals, appropriately timed allergenic food introduction

Язык: Английский

---